OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Allergy and Clinical Immunology-In Practice is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Telemedicine in the Era of COVID-19	420
mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach	317
COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic	225
A Consensus Approach to the Primary Prevention of Food Allergy Through Nutrition: Guidance from the American Academy of Allergy, Asthma, and Immunology; American College of Allergy, Asthma, and Immuno	165
US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema	156
Chronic Rhinosinusitis with Nasal Polyps and Asthma	148
Polyethylene Glycol–Induced Systemic Allergic Reactions (Anaphylaxis)	147
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach	146
Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic	140
Global Trends in Anaphylaxis Epidemiology and Clinical Implications	136
Exercise and Fitness in the Age of Social Distancing During the COVID-19 Pandemic	129
Clinician Wellness During the COVID-19 Pandemic: Extraordinary Times and Unusual Challenges for the Allergist/Immunologist	126
Risk Communication During COVID-19	126
Initial effects of the COVID-19 pandemic on pediatric asthma emergency department utilization	122
Prevalence of Food Sensitization and Food Allergy in Children Across Europe	109
Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden	109
Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness	108
Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis	101
First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing	101
Long-Term Therapy Response to Anti–IL-5 Biologics in Severe Asthma—A Real-Life Evaluation	100
Pediatric Asthma Health Care Utilization, Viral Testing, and Air Pollution Changes During the COVID-19 Pandemic	100
Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs	99
Asthma prolongs intubation in COVID-19	96
Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients	96
Food Allergy from Infancy Through Adulthood	91

Anti-PEG IgE in anaphylaxis associated with polyethylene glycol	83
Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis	79
The Impact of Social Determinants of Health on Children with Asthma	79
Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis	78
The Challenges and Opportunities for Shared Decision Making Highlighted by COVID-19	76
Temporal trends in prevalence of food allergy in Canada	76
SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation	72
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis	71
Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity	71
Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect	69
Improving Diagnostic Accuracy in Food Allergy	69
Hereditary Alpha-Tryptasemia: UK Prevalence and Variability in Disease Expression	69
Clinical Relevance of Cross-Reactivity in Food Allergy	69
Phenotypes of Chronic Rhinosinusitis	68
Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma	67
Defining a Severe Asthma Super-Responder: Findings from a Delphi Process	67
Rapid recovery of a SARS-CoV-2–infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma	66
Systematic Review of Digital Interventions for Pediatric Asthma Management	64
Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City	64
Endotypes of Chronic Rhinosinusitis with Nasal Polyps: Pathology and Possible Therapeutic Implications	63
Biologics for the Use in Chronic Spontaneous Urticaria: When and Which	62
Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies	62
The Pathogenesis of Chronic Spontaneous Urticaria: The Role of Infiltrating Cells	62
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes	61
Health-Related Quality of Life in Common Variable Immunodeficiency Italian Patients Switched to Remote Assistance During the COVID-19 Pandemic	61
Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)	60
Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan	59
COVID-19 Susceptibility in Bronchial Asthma	59
Work Group Report: COVID-19: Unmasking Telemedicine	58
Reduction of allergic rhinitis symptoms with face mask usage during the COVID-19 pandemic	57
Comparative Study of Food Allergies in Children from China, India, and Russia: The EuroPrevall-INCO Surveys	55